NCT00365053View on ClinicalTrials.gov

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Advanced Malignant MesotheliomaEpithelial MesotheliomaRecurrent Malignant MesotheliomaSarcomatous Mesothelioma
Interventions
DRUG

belinostat

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91010

City of Hope, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00365053 - PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter